Showing results (131-140 of 139) with videos related to
Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
The Lancet. Gastroenterology & Hepatology|January 17, 2025
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trialJohn W K Chia, Eva Segelov, Yanhong Deng, et al.Journal for Immunotherapy of Cancer|March 9, 2026
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancersChanghoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.Gut|January 12, 2021
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinomaShuichi Aoki, Koetsu Inoue, Sebastian Klein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialCristina Saura, Mafalda Oliveira, Yin-Hsun Feng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.Hepatology International|November 21, 2024
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024George Lau, Shuntaro Obi, Jian Zhou, et al.Pageof 14